SJS Investment Consulting’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.79K Sell
75
-6
-7% -$503 ﹤0.01% 1257
2026
Q1
$6.49K Sell
81
-11
-12% -$907 ﹤0.01% 974
2025
Q4
$7.84K Buy
92
+72
+360% +$5.91K ﹤0.01% 844
2025
Q3
$1.56K Hold
20
﹤0.01% 887
2025
Q2
$1.56K Sell
20
-40
-67% -$2.98K ﹤0.01% 648
2025
Q1
$4.35K Buy
60
+5
+9% +$358 ﹤0.01% 491
2024
Q4
$4.07K Buy
55
+34
+162% +$2.38K ﹤0.01% 471
2024
Q3
$1.39K Buy
21
+9
+75% +$654 ﹤0.01% 949
2024
Q2
$1.11K Hold
12
﹤0.01% 989
2024
Q1
$1.15K Buy
12
+1
+9% +$84 ﹤0.01% 987
2023
Q4
$839 Hold
11
﹤0.01% 1026
2023
Q3
$763 Sell
11
-1
-8% -$80 ﹤0.01% 1042
2023
Q2
$1.13K Sell
12
-19
-61% -$1.65K ﹤0.01% 849
2023
Q1
$2.57K Sell
31
-1
-3% -$79 ﹤0.01% 527
2022
Q4
$2.39K Buy
32
+6
+23% +$462 ﹤0.01% 552
2022
Q3
$2K Buy
+26
New +$2.5K ﹤0.01% 456
2022
Q1
$46K Buy
392
+199
+103% +$22.3K 0.01% 188
2021
Q4
$25K Buy
+193
New +$22.5K 0.01% 243

Other funds holding EW

SJS Investment Consulting's EW Position: Q2 2026 in Review

SJS Investment Consulting reduced its Edwards Lifesciences (EW) stake by 7.4% in Q2 2026, selling an estimated $503 and leaving 75 shares worth $6.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1257.

SJS Investment Consulting first reported a position in EW in Q4 2021 and has held it in 18 quarters since. The position peaked at $46K in Q1 2022. 826 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • SJS Investment Consulting held 75 shares of Edwards Lifesciences worth $6.79K as of Q2 2026.
  • SJS Investment Consulting sold 6 Edwards Lifesciences shares in Q2 2026, an estimated $503.
  • Edwards Lifesciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1257 holding.
  • SJS Investment Consulting first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 18 quarters since.
  • SJS Investment Consulting's Edwards Lifesciences position peaked at $46K in Q1 2022.
  • 826 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.